Cue restricted smoking increases quit rates with varenicline
Open Access
- 13 May 2021
- journal article
- research article
- Published by E.U. European Publishing in Tobacco Prevention & Cessation
- Vol. 7 (May), 1-10
- https://doi.org/10.18332/tpc/133570
Abstract
Introduction: Varenicline effectively helps smokers quit by reducing withdrawal symptoms and blocking the reward of smoking. However, most quitters return to smoking within one year. ‘Cue Restricted Smoking’ is a behavioral technique designed to increase quit rates by asking smokers...Keywords
This publication has 20 references indexed in Scilit:
- Neurobiological Bases of Cue- and Nicotine-induced Reinstatement of Nicotine Seeking: Implications for the Development of Smoking Cessation MedicationsPublished by Springer Science and Business Media LLC ,2015
- Managing tobacco use: the neglected cardiovascular disease risk factorEuropean Heart Journal, 2013
- Pharmacological interventions for smoking cessation: an overview and network meta-analysisEmergencias, 2013
- Effectiveness of Coadministration of Varenicline, Bupropion, and Serotonin Reuptake Inhibitors in a Smoking Cessation Program in the Real-Life SettingNicotine & Tobacco Research, 2012
- Impact of varenicline on cue-specific craving assessed in the natural environment among treatment-seeking smokersPsychopharmacology, 2012
- A systematic review of longitudinal studies on the association between depression and smoking in adolescentsBMC Public Health, 2009
- Varenicline and bupropion sustained-release combination therapy for smoking cessationNicotine & Tobacco Research, 2009
- Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking CessationA Randomized Controlled TrialJAMA, 2006
- Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking CessationJournal of Medicinal Chemistry, 2005
- Why people smokeBMJ, 2004